Pfizer share surge 12%; special dividend announced and profit jumps 85%; check the record date for dividend

Pfizer shares soared 12% to a 4-month high after the company announced a ₹165 per share dividend, including special dividend. The pharma giant also reported an 85% jump in Q4 profit. 

Overview of Pfizer Ltd in India

Pfizer Ltd, one of India’s largest multinational pharmaceutical companies, has a strong presence in the healthcare sector with a portfolio of over 150 products across 15 therapeutic areas. Its leading brands include Prevenar 13, Corex – DX, Dolonex, Enbrel, Becosules, and Folvite. In addition to its commercial operations, the company operates a state-of-the-art, award-winning manufacturing facility in Goa, which produces more than a billion tablets annually.

Pfizer Share Price Hits 4-Month High

On Tuesday, May 20, as of 12:17 PM, shares of Pfizer Ltd surged by 12%, marking their sharpest single-day gain since 2018. This rally led the stock to reach a fresh four-month high and was largely driven by two key factors: a substantial dividend declaration and better-than-expected quarterly earnings. 

Pfizer Dividend Announcement and Record Date 

The company announced a total dividend of ₹165 per equity share, which translates to a 1,650% payout on the face value of ₹10. The dividend includes a final dividend of ₹35 per share, a special dividend of ₹100 in celebration of Pfizer’s 75th year in India, and an additional ₹30 per share from gains related to the transfer of leasehold land and buildings. The record date to determine eligible shareholders for this dividend has been fixed as July 9, 2025.

Pfizer Q4FY25 Results: Profit Up 85% Y-o-Y

In terms of financial performance, Pfizer reported a robust 85% year-on-year increase in net profit for the March quarter of FY25, with profits rising to ₹331 crore compared to ₹179 crore in Q4FY24. Revenue from operations also saw a growth of 8.3%, increasing to ₹591.9 crore in Q4FY25 from ₹546.6 crore in the same quarter the previous year.

Disclaimer: The article is for informational purposes only and not investment advice.